YABAO PHARM.CORP: Sitagliptin Metformin Extended-Release Tablets have obtained the drug registration certificate
I'm PortAI, I can summarize articles.
YABAO PHARM.CORP announced that its wholly-owned subsidiary Beijing YABAO Biopharmaceutical Co., Ltd. has obtained the drug registration certificate for Sitagliptin Metformin Extended-Release Tablets issued by the National Medical Products Administration. This medication is suitable for adult patients with type 2 diabetes, used in combination with Sitagliptin and Metformin. Sitagliptin Metformin Extended-Release Tablets were developed by MERCK SHARP DOHME and were approved for sale in the United States in 2012 under the brand name JANUMETXR®. It is expected that the sales of this drug in the domestic market will reach 921 million yuan in 2024
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments